# OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time

> **NCT06216821** · NA · RECRUITING · sponsor: **Shenyang Northern Hospital** · enrollment: 3490 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** standard DAPT
- **DRUG:** OPT-CAD score guided DAPT de-escalation

## Key facts

- **NCT ID:** NCT06216821
- **Lead sponsor:** Shenyang Northern Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 3490 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06216821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06216821, "OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06216821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*